RAPH RAPHAEL PHARMACEUTICAL INC.
Company Updates ·
Ajay Kumar Dhadha resigned as chairman effective June 30, 2026. Guy Ofir resigned as chief financial officer and general counsel effective July 16, 2026, and the company appointed Uri Tadelis as CFO.
We have not published a story on RAPHAEL PHARMACEUTICAL INC. yet. When there is news, it will appear here.
Raphael Pharmaceutical Inc. is a pharmaceutical research and development company focused on drug therapies based on cannabinoids, including cannabidiol (CBD) oil. Its lead product candidate treats rheumatoid arthritis (RA). The company says a single-group study of its formula in patients with active RA, run in the U.S., was completed in December 2024 and suggested possible benefits for symptom management and well-being. In August 2025 the company announced the launch of a natural formula under the RaphaWell brand, sold as a clinically tested dietary supplement for RA support. The company also aims to develop a treatment for asthma, building on pre-clinical studies at Rambam Health Care Campus. A provisional patent application filed in November 2025 with the Medical Cannabis Research and Innovation Center and Rambam covers neutrophil-dominant autoimmune diseases, including RA, psoriatic arthritis, inflammatory bowel disease, systemic lupus erythematosus with neutrophil involvement and gout. The company intends to seek FDA approval first and European Medicines Agency approval afterward.
| Product or program | What it is | Stage |
|---|---|---|
| Raphael's Formula | Cannabinoid-based formula studied for patients with active rheumatoid arthritis | proof-of-concept clinical study completed December 2024 |
| RaphaWell | Natural, plant-based dietary supplement for rheumatoid arthritis support in the U.S. | launch announced August 2025 |
| Asthma treatment | Novel cannabinoid-based treatment the company aims to develop | in development; pre-clinical studies at Rambam |
| Line | FY2025 | FY2024 |
|---|---|---|
| Research and development | $631,000 | $776,000 |
| Net income (loss) | -$1.3 million | -$1.5 million |
| Cash from operations | -$210,000 | -$532,000 |
| Cash and equivalents | $45,000 | $19,000 |
RAPHAEL PHARMACEUTICAL INC. trades under the ticker RAPH on OTC.
RAPHAEL PHARMACEUTICAL INC. is listed on OTC.
The SEC Central Index Key (CIK) for RAPHAEL PHARMACEUTICAL INC. is 1415397. Its filings are on SEC EDGAR.
20,176,418 shares as of 2026-08-14, per the cover page of its 10-Q filed 2026-08-14.
Our directory records RAPHAEL PHARMACEUTICAL INC. under Israel.
Our directory classifies RAPHAEL PHARMACEUTICAL INC. as: Biopharma / pharmaceutical profile checked. This is a directory classification, not a description of the pipeline.
The ISIN recorded for RAPHAEL PHARMACEUTICAL INC. is US27785B2088.
aibio.space lists RAPHAEL PHARMACEUTICAL INC. among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as NV.
Raphael Pharmaceutical Inc. is a pharmaceutical research and development company focused on drug therapies based on cannabinoids, including cannabidiol (CBD) oil. Its lead product candidate treats rheumatoid arthritis (RA).
Raphael's Formula: Cannabinoid-based formula studied for patients with active rheumatoid arthritis Stage: proof-of-concept clinical study completed December 2024.
RaphaWell: Natural, plant-based dietary supplement for rheumatoid arthritis support in the U.S. Stage: launch announced August 2025.
RAPHAEL PHARMACEUTICAL INC. reported a net loss of $1.3 million for the fiscal year ended Dec 31, 2025, and used $210,000 of cash in operations, per its annual report to the SEC.
$631,000 in the fiscal year ended Dec 31, 2025, per its annual report.
$1,000 in cash at Jun 30, 2026, per its 10-Q.
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio